170 results on '"Maurer, M."'
Search Results
2. REMIBRUTINIB ACHIEVES CLINICALLY SIGNIFICANT RESPONSE IN CHRONIC SPONTANEOUS URTICARIA PATIENTS REGARDLESS OF PRIOR ORAL TREATMENTS
3. DEUCRICTIBANT IMMEDIATE-RELEASE CAPSULE REDUCES TIME TO END OF PROGRESSION OF HEREDITARY ANGIOEDEMA ATTACKS’ MANIFESTATIONS
4. REMIBRUTINIB SHOWED GOOD STABILITY OF RESPONSE IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY
5. DIAGNOSING HEREDITARY ANGIOEDEMA (HAE) WITH NORMAL C1-INH (HAE-NC1-INH) – A REAL WORLD ACARE SURVEY
6. REMIBRUTINIB PROVIDES FAST AND CLINICALLY IMPORTANT IMPROVEMENT OF CHRONIC SPONTANEOUS URTICARIA DISEASE ACTIVITY
7. FAST SYMPTOM IMPROVEMENT AND FAVORABLE SAFETY PROFILE WITH REMIBRUTINIB IN CHRONIC SPONTANEOUS URTICARIA: REMIX-1/-2 STUDIES
8. REFINING PREVALENCE ESTIMATES OF HEREDITARY ANGIOEDEMA (HAE) WITH NORMAL C1-INH (HAE-NC1-INH)
9. EFFICACY AND SAFETY OF CT-P39 COMPARED TO REFERENCE OMALIZUMAB IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA
10. REMIBRUTINIB TREATMENT IMPROVES HIVE SEVERITY IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA: PHASE 2B STUDY RESULTS
11. Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting
12. WHAT ARE PATIENTS SEARCHING ON INTERNET IN RELATION TO URTICARIA? AN INFODEMIOLOGY ANALYSIS
13. SUSTAINED IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE WITH CONTINUED LANADELUMAB TREATMENT IN HEREDITARY ANGIOEDEMA
14. BARRIERS OF USE OF PROMS AMONG ALLERGISTS WHO TREAT ATOPIC DERMATITIS AND CHRONIC URTICARIA
15. REMIBRUTINIB TREATMENT IMPROVES SLEEP AND ACTIVITY IN CHRONIC SPONTANEOUS URTICARIA PATIENTS: PHASE 2B STUDY RESULTS
16. DUPILUMAB EFFICACY IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA BY IGE LEVEL: LIBERTY-CSU CUPID STUDY A
17. FREEDOM FROM ITCH AND HIVES IN CHRONIC SPONTANEOUS URTICARIA IS ASSOCIATED WITH IMPROVED QUALITY-OF-LIFE MEASURES
18. REMIBRUTINIB IMPROVES CHRONIC SPONTANEOUS URTICARIA IN PATIENTS IRRESPECTIVE OF CU-INDEX: RESULTS FROM PHASE 2B STUDY
19. REMIBRUTINIB IMPROVES CHRONIC SPONTANEOUS URTICARIA IN PATIENTS WITH LOW OR HIGH IGE
20. LONG-TERM TREATMENT OF HEREDITARY ANGIOEDEMA ATTACKS WITH ORAL DEUCRICTIBANT: RAPIDE-2 EXTENSION STUDY RESULTS
21. CORRELATION OF TIME TO TREATMENT WITH ATTACK DURATION IN THE SEBETRALSTAT PHASE 3 KONFIDENT TRIAL
22. IMPROVING THE QUALITY OF CARE FOR PATIENTS WITH CSU: STUDY DESIGN AND PATIENT BASELINE CHARACTERISTICS
23. STAR-0215 INDUCES RAPID IMPROVEMENTS OF QUALITY OF LIFE IN HAE PATIENTS IN THE ALPHA-STAR TRIAL
24. CT-P39 COMPARED TO REFERENCE OMALIZUMAB IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA; 40-WEEK RESULTS
25. Positive efficacy and favorable safety of barzolvolimab in chronic inducible urticaria: phase II trial results
26. NO CLINICALLY MEANINGFUL IMPACT OF REMIBRUTINIB ON IMMUNOGLOBULIN LEVELS OR INFECTIONS IN CHRONIC SPONTANEOUS URTICARIA.
27. P047 COMPLETE RESPONSE WITH LIGELIZUMAB IN CHRONIC SPONTANEOUS URTICARIA: A COMPOSITE SCORE OF SYMPTOMS AND QUALITY-OF-LIFE
28. P049 LIGELIZUMAB ACHIEVES FREEDOM FROM DISEASE ACTIVITY IN CHRONIC SPONTANEOUS URTICARIA REGARDLESS OF PREVIOUS H1-ANTIHISTAMINE DOSE
29. ANALYSIS OF SAFETY DATA OF REMIBRUTINIB FROM COMPLETED PHASE 2 STUDIES IN INFLAMMATORY IMMUNE-MEDIATED DISEASES
30. TREATMENT OF HEREDITARY ANGIOEDEMA (HAE) WITH NORMAL C1-INH (HAE-NC1-INH) – A REAL-WORLD ACARE SURVEY
31. D102 BEROTRALSTAT REDUCES ATTACKS IN PATIENTS WITH HEREDITARY ANGIOEDEMA (HAE): APEX-2 TRIAL 48 WEEK RESULTS
32. D101 EFFICACY OF LIGELIZUMAB IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH OMALIZUMAB
33. P153 COMPLETE CONTROL OF URTICARIA SYMPTOMS WITH LIGELIZUMAB HELPS NORMALIZE QUALITY OF LIFE
34. D100 LIGELIZUMAB ACHIEVES FAST CONTROL OF SYMPTOMS IN MORE PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA VERSUS OMALIZUMAB
35. P155 SLEEP AND QUALITY OF LIFE IMPROVES WITH BETTER CONTROL OF URTICARIA SYMPTOMS: LIGELIZUMAB PHASE-2B STUDIES
36. P157 ATTACK-FREE STATUS DURING EXTENDED TREATMENT WITH LANADELUMAB FOR HEREDITARY ANGIOEDEMA: HELP OLE STUDY FINAL RESULTS
37. FAVORABLE EFFICACY AND SAFETY PROFILE OF AVAPRITINIB IS MAINTAINED IN THE CONTEXT OF OMALIZUMAB TREATMENT
38. AVAPRITINIB BENEFIT IN PATIENTS WITH MODERATE SYMPTOMS OF INDOLENT SYSTEMIC MASTOCYTOSIS: SUBGROUP ANALYSIS FROM PIONEER
39. P152 CLINICAL ACTIVITY OF AK002, AN ANTI-SIGLEC-8 ANTIBODY, IN MULTIPLE FORMS OF UNCONTROLLED CHRONIC URTICARIA
40. P150 ORAL PROPHYLAXIS WITH BCX7353 REDUCES HAE ATTACK RATES AND IS WELL-TOLERATED: APEX-2 STUDY RESULTS
41. P154 SAFETY AND TOLERABILITY OF ONCE-DAILY ORAL KALLIKREIN INHIBITOR BCX7353 IN PHASE 3 APEX-2 HAE STUDY
42. P156 LONG-TERM LANADELUMAB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE: HELP OPEN-LABEL EXTENSION STUDY INTERIM FINDINGS
43. RELATIONSHIP OF TARGET CONCENTRATIONS WITH EFFICACY: RESULTS FROM THE APEX-1 STUDY OF BCX7353
44. LANADELUMAB 300MG EVERY 2 WEEKS EFFECTIVELY PREVENTED HEREDITARY ANGIOEDEMA ATTACKS IN THE HELP STUDY
45. SUBCUTANEOUS SELF-ADMINISTRATION OF LANADELUMAB FOR PROPHYLACTIC TREATMENT IN PATIENTS WITH HEREDITARY ANGIOEDEMA (HAE)
46. P507 BCX7353: An effective and safe oral prophylaxis against attacks of hereditary angioedema. apex-1 final results
47. OR034 Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study
48. P164 Longitudinal natural history of patients with type I/II hereditary angioedema: icatibant outcome survey data
49. P161 Urticaria activity and impact measure (U-aim) evaluates CSU/CIU activity, impact, and control in clinical practice
50. O004 Childhood presenting hereditary angioedema is diagnosed in adulthood by non-pediatric physicians: Icatibant outcome survey findings
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.